DK1240326T3 - Udlösende receptor der er involveret i naturlig cytotoxicitet medieret af humane naturlige dræberceller og antistoffer som identificerer denne receptor - Google Patents

Udlösende receptor der er involveret i naturlig cytotoxicitet medieret af humane naturlige dræberceller og antistoffer som identificerer denne receptor

Info

Publication number
DK1240326T3
DK1240326T3 DK00989877T DK00989877T DK1240326T3 DK 1240326 T3 DK1240326 T3 DK 1240326T3 DK 00989877 T DK00989877 T DK 00989877T DK 00989877 T DK00989877 T DK 00989877T DK 1240326 T3 DK1240326 T3 DK 1240326T3
Authority
DK
Denmark
Prior art keywords
receptor
antibodies
identify
killer cells
involved
Prior art date
Application number
DK00989877T
Other languages
Danish (da)
English (en)
Inventor
Alessandro Moretta
Cristina Bottino
Roberto Biassoni
Original Assignee
Innate Pharma
Univ Genova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA2288307A external-priority patent/CA2288307C/en
Application filed by Innate Pharma, Univ Genova filed Critical Innate Pharma
Application granted granted Critical
Publication of DK1240326T3 publication Critical patent/DK1240326T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK00989877T 1999-11-15 2000-11-15 Udlösende receptor der er involveret i naturlig cytotoxicitet medieret af humane naturlige dræberceller og antistoffer som identificerer denne receptor DK1240326T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44051499A 1999-11-15 1999-11-15
CA2288307A CA2288307C (en) 1999-11-15 1999-11-15 Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same
PCT/EP2000/011697 WO2001036630A2 (en) 1999-11-15 2000-11-15 Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same

Publications (1)

Publication Number Publication Date
DK1240326T3 true DK1240326T3 (da) 2009-06-02

Family

ID=25681295

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00989877T DK1240326T3 (da) 1999-11-15 2000-11-15 Udlösende receptor der er involveret i naturlig cytotoxicitet medieret af humane naturlige dræberceller og antistoffer som identificerer denne receptor

Country Status (8)

Country Link
EP (1) EP1240326B1 (es)
JP (1) JP4776845B2 (es)
AT (1) ATE423848T1 (es)
AU (1) AU783899B2 (es)
DE (1) DE60041655D1 (es)
DK (1) DK1240326T3 (es)
ES (1) ES2321687T3 (es)
WO (1) WO2001036630A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10261223A1 (de) * 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
JP2006514024A (ja) * 2002-12-23 2006-04-27 イネイト・ファーマ Ｎｋ細胞の増殖に対する効果を有する医薬組成物及びそれを使用する方法
EP1445614A1 (en) * 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) A method for the in vitro assessment of the progression status of an HIV virus in an invidual
CN104645327A (zh) 2003-07-24 2015-05-27 依奈特制药公司 使用nk细胞增效化合物提高治疗性抗体功效的方法和组合物
AU2005238298A1 (en) * 2004-04-30 2005-11-10 Innate Pharma Compositions and methods for enhancing NK cell activity
KR20070050911A (ko) * 2004-06-18 2007-05-16 제넨테크, 인크. Ａｐｏ２ｌ 수용체 작동제 및 ｎｋ 세포 활성화제의 사용방법
US7732131B2 (en) 2004-08-03 2010-06-08 Innate Pharma S.A. Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor
EP1626059A1 (en) * 2004-08-09 2006-02-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2
CA2591059C (en) 2004-12-28 2018-11-06 Innate Pharma Monoclonal antibodies against nkg2a
WO2007042573A2 (en) 2005-10-14 2007-04-19 Innate Pharma Compositions and methods for treating proliferative disorders
EP3241846B1 (en) * 2007-10-04 2022-02-23 ZymoGenetics, Inc. B7 family member zb7h6 and related compositions and methods
CA2990520C (en) * 2015-07-24 2023-06-27 Innate Pharma Methods for detecting tissue infiltrating nk cells
EP3713959A1 (en) 2017-11-21 2020-09-30 Innate Pharma Multispecific antigen binding proteins
EP4448095A1 (en) 2021-12-14 2024-10-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0714510B1 (en) * 1993-08-27 2002-06-19 Dana Farber Cancer Institute Natural killer cell-specific antigen and antibodies that identify the same
ZA9810133B (en) * 1997-11-07 1999-05-17 Biogen Inc BMOG a novel protein member of the myelin-oligodendrocyte glycoprotein family and its use for ummonomodulatory purposes
CA2325735C (en) * 1998-03-27 2013-06-04 Gabriele Multhoff Hsp70 protein for the treatment of tumours, cancer or infectious diseases through nk-cell activation

Also Published As

Publication number Publication date
AU2667701A (en) 2001-05-30
JP2003523735A (ja) 2003-08-12
WO2001036630A2 (en) 2001-05-25
DE60041655D1 (de) 2009-04-09
WO2001036630A3 (en) 2001-11-08
EP1240326A2 (en) 2002-09-18
ES2321687T3 (es) 2009-06-10
ATE423848T1 (de) 2009-03-15
AU783899B2 (en) 2005-12-22
WO2001036630A9 (en) 2002-09-19
EP1240326B1 (en) 2009-02-25
JP4776845B2 (ja) 2011-09-21

Similar Documents

Publication Publication Date Title
DK1240326T3 (da) Udlösende receptor der er involveret i naturlig cytotoxicitet medieret af humane naturlige dræberceller og antistoffer som identificerer denne receptor
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
AR029605A1 (es) DERIVADOS DE DIFENILUREA SUBSTITUIDOS CON SULFONAMIDA , COMPOSICIoN FARMACEUTICA , USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO uTILES COMO ANTAGONISTA DE RECEPTORES DE IL-8, COMPUESTOS, INTERMEDIARIOS, Y MÉTODOS DE CONVERSIoN DE COMPUESTOS
ATE450508T1 (de) Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
DK1639013T3 (da) Pan-kir2dl-nk-receptor-antistoffer og anvendelse heraf til diagnosticering og terapi
BRPI0409133A (pt) formulações farmacêuticas contendo metilnaltrexona
UY27720A1 (es) Aroilpiridinonas monocíclicas,
BR0208150A (pt) Antagonistas de mch e sua aplicação no tratamento da obesidade
IS6750A (is) Samrunnin heterósýklísk súkkínímíð efnasambönd oghliðstæður þeirra, stillar fyrir starfsemi kjarnahormónaviðtaka
SE0301653D0 (sv) Novel compounds
DK0817847T3 (da) IL-17-receptor
EE05287B1 (et) Tsklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
DK1599478T3 (da) Dihydropteridinoner, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemiddel
CR9266A (es) Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos
ID26984A (id) Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
DE60227068D1 (de) Therapeutische verfahren unter verwendung von pflanzlichen zusammensetzungen
PT1506185E (pt) Compostos novos e sua utilizacao
RS51271B (sr) Čvrsta farmaceutska kompozicija koja sadrži donepezil hidrohlorid
ATE537249T1 (de) Wiedergewinnung von gewebefunktion nach verabreichung von b-zellen an verletztes gewebe
NO20042158L (no) Substituert 4-fenyl-tetrahydroisokinoliner, fremgangsmate for fremstilling derav, anvendelse derav som medikamenter, i tillegg til medikamenter inneholdende samme
IL164464A0 (en) Antagonists to mcp proteins, their preparation, pharmaceutical composition containing them, and their use
CL2003002678A1 (es) Compuestos derivados de piperidina, moduladores de la actividad del receptor ccr5; procedimiento de preparacion; composicion farmaceutica, y su uso en el tratamiento de enfermedades inmunologicas, inflamatorias, asma, artritis reumatoidea y ateroescl
NZ514696A (en) IL-8 receptor antagonists
MX9204613A (es) Nitratos organicos, procedimientos para su preparacion y su uso en el tratamiento de enfermedades cardiovasculares
ATE384066T1 (de) Thieno-pyrrole verbindungen als antagonisten der gonadotropin-freisetzenden hormonrezeptoren